Le Lézard
Classified in: Health
Subjects: AVO, CPG, CFG

Canadian physicians support national licensure and increased use of technology to improve health care access


OTTAWA, Oct. 29, 2019 /CNW/ - New data released today by the Canadian Medical Association (CMA) shows overwhelming support for national physician licensure. The findings, from the 2019 CMA Physician Workforce Survey, reveal that nine in 10 physicians support national licensure and three quarters agree it will improve access to care for Canadians. Nearly 7,000 physicians responded to the survey and provided input on the realities of their practice ? from the potential impact of technology to working hours and patient care.

"Physicians are prepared to embrace technology to alleviate the strain on our health care system," says Dr. Sandy Buchman, CMA president. "The potential that technology, such as virtual care, can offer to increase access to care is obvious and it's time to put this technology to work, for all our benefit."

Under current rules in most jurisdictions, physicians must currently be licensed in the jurisdiction where the patient they are treating resides. In order to provide care for patients in other jurisdictions, they must secure an additional license or licenses, a costly and time-consuming process that can impact access to care.

Among the report's key findings:

National licensure:

Access to technology:

The 2019 CMA Physician Workforce Survey was conducted between March and May 2019. 6,762 physicians responded and the survey results are considered accurate to within 1.2 percentage points, 19 times out of 20.

Since 1867, the Canadian Medical Association has been the national voice of Canada's medical profession. We work with physicians, residents and medical students on issues that matter to the profession and the health of Canadians. We advocate for policy and programs that drive meaningful change for physicians and their patients.

SOURCE Canadian Medical Association


These press releases may also interest you

at 09:35
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019...

at 09:33
Oncopeptides AB  will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an overall response rate (ORR) of 29% and clinical benefit rate (CBR) of 37% in patients with...

at 09:05
ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced new results from the hematological portion of the ALX148 Phase 1 program at the 2019 ASH Annual Meeting [publication...

at 09:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data on two investigational CD20-CD3 T-cell engaging bispecific antibodies, mosunetuzumab and CD20-TCB, in people with relapsed or refractory (R/R) B-cell...

at 09:05
Sangamo Therapeutics, Inc. , a genomic medicine company, and Pfizer, Inc. , today announced updated follow-up results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patients with severe hemophilia A. The data showed...

at 09:05
Verastem, Inc. (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced the presentation of key...



News published on 29 october 2019 at 10:20 and distributed by: